We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Moderna (MRNA) Fell More Than Broader Market
Read MoreHide Full Article
In the latest close session, Moderna (MRNA - Free Report) was down 5.05% at $213.63. The stock fell short of the S&P 500, which registered a loss of 0.06% for the day. On the other hand, the Dow registered a gain of 0.38%, and the technology-centric Nasdaq decreased by 0.44%.
The biotechnology company's stock has climbed by 56.28% in the past month, exceeding the Medical sector's gain of 0.04% and the S&P 500's gain of 2.36%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company's upcoming EPS is projected at -$1.37, signifying a 168.63% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $888.78 million, down 12.52% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.52 per share and a revenue of $2.1 billion, indicating changes of -17.36% and +8.27%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.35% lower within the past month. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 166, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Moderna (MRNA) Fell More Than Broader Market
In the latest close session, Moderna (MRNA - Free Report) was down 5.05% at $213.63. The stock fell short of the S&P 500, which registered a loss of 0.06% for the day. On the other hand, the Dow registered a gain of 0.38%, and the technology-centric Nasdaq decreased by 0.44%.
The biotechnology company's stock has climbed by 56.28% in the past month, exceeding the Medical sector's gain of 0.04% and the S&P 500's gain of 2.36%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company's upcoming EPS is projected at -$1.37, signifying a 168.63% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $888.78 million, down 12.52% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.52 per share and a revenue of $2.1 billion, indicating changes of -17.36% and +8.27%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.35% lower within the past month. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 166, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.